Compare Stocks → BREAKING – Pentagon to Spend $20 Billion on “Distributed AI” (From Behind the Markets) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:BCLINASDAQ:TALSNASDAQ:TCRRNASDAQ:UPTD Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCLIBrainstorm Cell Therapeutics$0.43+16.2%$0.49$0.13▼$3.34$29.39M0.4979,507 shs1.34 million shsTALSTalaris Therapeutics$15.78+1.6%$18.84$0.89▼$27.95$674.82M2.18386,531 shs226,396 shsTCRRTCR2 Therapeutics$1.48-5.7%$1.65$0.82▼$3.88$58.11M1.95494,777 shs3.91 million shsUPTDTradeUP Acquisition$1.03+3.0%$1.51$6.88▼$33.00$2.23M0.12270,115 shs15,240 shs7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCLIBrainstorm Cell Therapeutics-1.60%-2.52%-43.47%-4.17%-87.48%TALSTalaris Therapeutics-1.96%-1.90%-31.31%-57.86%+419.40%TCRRTCR2 Therapeutics0.00%0.00%0.00%0.00%-24.49%UPTDTradeUP Acquisition0.00%-6.45%-13.04%-20.00%-90.65%“Crash Insurance” For Your Retirement (Ad)When it comes to retirement, everyone fears one thing… Outliving their retirement savings. You'll discover conservative, beginner-friendly options strategies which could help to cash flow your stock portfolio. Click here to register for free.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBCLIBrainstorm Cell Therapeutics0.3666 of 5 stars0.03.00.04.70.00.00.6TALSTalaris TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ATCRRTCR2 TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AUPTDTradeUP AcquisitionN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCLIBrainstorm Cell Therapeutics2.00HoldN/AN/ATALSTalaris TherapeuticsN/AN/AN/AN/ATCRRTCR2 TherapeuticsN/AN/AN/AN/AUPTDTradeUP AcquisitionN/AN/AN/AN/ACurrent Analyst RatingsSales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCLIBrainstorm Cell TherapeuticsN/AN/AN/AN/A($0.08) per shareN/ATALSTalaris TherapeuticsN/AN/AN/AN/A$4.33 per shareN/ATCRRTCR2 TherapeuticsN/AN/AN/AN/A$2.58 per shareN/AUPTDTradeUP AcquisitionN/AN/AN/AN/A($1.59) per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCLIBrainstorm Cell Therapeutics-$17.19M-$0.41N/AN/AN/AN/AN/A-376.40%5/20/2024 (Estimated)TALSTalaris Therapeutics-$73.89M-$1.79N/A∞N/AN/A-39.93%-37.37%N/ATCRRTCR2 Therapeutics-$151.82M-$4.20N/AN/AN/AN/A-97.81%-69.35%N/AUPTDTradeUP Acquisition-$1MN/A0.00∞N/AN/AN/A-3.38%N/ALatest TCRR, BCLI, UPTD, and TALS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/1/2024Q4 2023BCLIBrainstorm Cell Therapeutics-$0.15-$0.11+$0.04-$0.11N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBCLIBrainstorm Cell TherapeuticsN/AN/AN/AN/AN/ATALSTalaris TherapeuticsN/AN/AN/AN/AN/ATCRRTCR2 TherapeuticsN/AN/AN/AN/AN/AUPTDTradeUP AcquisitionN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBCLIBrainstorm Cell TherapeuticsN/A0.240.24TALSTalaris TherapeuticsN/A15.4115.41TCRRTCR2 TherapeuticsN/A2.962.96UPTDTradeUP AcquisitionN/A0.090.09OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCLIBrainstorm Cell Therapeutics14.33%TALSTalaris Therapeutics67.61%TCRRTCR2 Therapeutics64.76%UPTDTradeUP Acquisition34.95%Insider OwnershipCompanyInsider OwnershipBCLIBrainstorm Cell Therapeutics5.45%TALSTalaris Therapeutics16.50%TCRRTCR2 Therapeutics25.01%UPTDTradeUP Acquisition55.10%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableBCLIBrainstorm Cell Therapeutics2968.34 million64.62 millionOptionableTALSTalaris Therapeutics8442.76 million35.71 millionNot OptionableTCRRTCR2 Therapeutics13739.26 million29.44 millionNot OptionableUPTDTradeUP Acquisition2,0212.17 million973,000Not OptionableTCRR, BCLI, UPTD, and TALS HeadlinesSourceHeadlineEstrella Immunopharma stock plunges in market debut after SPAC mergermsn.com - October 2 at 11:52 PMSPAC TradeUp, Estrella Biopharma complete merger; shares to debut Oct. 2msn.com - September 29 at 3:26 PMTradeUP Acquisition Corp. and Estrella Biopharma, Inc. Announce Completion of Business Combinationfinance.yahoo.com - September 29 at 3:26 PMTradeUP (UPTD) Stock is Up: What's Going On?benzinga.com - September 21 at 8:30 PMTradeUp (NASDAQ: UPTD) up 67% - Hey, maybe a deal really will be done heredhakatribune.com - September 15 at 4:38 PMWhy TradeUP Acquisition (UPTD) Stock Is Rocketing Higherbenzinga.com - September 1 at 3:19 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsBrainstorm Cell TherapeuticsNASDAQ:BCLIBrainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.Talaris TherapeuticsNASDAQ:TALSTalaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe blood, immune, and metabolic disorders. Its lead product candidate is FCR001, a novel allogeneic cell therapy that is in Phase II trial for living donor kidney transplant patients. The company is also developing FCR001 for the patients with a severe form of scleroderma. Talaris Therapeutics, Inc. was founded in 1988 and is headquartered in Wellesley, Massachusetts.TCR2 TherapeuticsNASDAQ:TCRRTCR2 Therapeutics, Inc. is a clinical-stage cell therapy company, which engages in the development of biological drugs and engineering T-cells for cancer therapy. It is also involved in the research and collaboration with academic laboratories and industry partners in the field of T-cell immunology, cell therapy, gene editing, and process development. The company was founded by Patrick A. Baeuerle on May 29, 2015 and is headquartered in Cambridge, MA.TradeUP AcquisitionNASDAQ:UPTDTradeUP Acquisition Corp. does not have significant operations. The company focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or other business combination with one or more businesses. The company was incorporated in 2021 and is based in New York, New York. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.